Statement: The PKU Association Ireland

The PKU Association Ireland (PKUAI) has been made aware that KUVAN® (sapropterin dihydrochloride) has been approved by the HSE Senior Leadership team and will be available in specific circumstances to our patient group for reimbursement from July 1st, 2019.

The PKUAI are currently awaiting receipt of the finalised document which outlines the specific circumstances under which patients will gain access. PKUAI welcomed the opportunity to represent the patient voice in the development of this document.

Once full details have been formally received, PKUAI look forward to providing a comprehensive update to the PKU Community via our communication channels (web-site and social media). 


PKU Association of Ireland

Tuesday 5 March, 2019